Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT05944783
PHASE4

Bioequivalence Studies of Dasatinib 100 Mg

Sponsor: Centro de Atencion e Investigacion Medica

View on ClinicalTrials.gov

Summary

A bioequivalence study of Dasatinib will be carried out in 46 healthy subjects, in fed condition, following the complete replicated design, randomized, comparative of 2 sequences, 2 study formulations, in a single dose of 100 mg of Dasatinib tablets / coated tablets, 4 periods. , with a washout time of 7 days between each dose

Official title: Bioequivalence Studies of Dasatinib 100 Mg Tablets in Healthy Colombian Subjects in Postprandial Condition

Key Details

Gender

MALE

Age Range

18 Years - 50 Years

Study Type

INTERVENTIONAL

Enrollment

46

Start Date

2025-09-01

Completion Date

2026-04-30

Last Updated

2025-02-12

Healthy Volunteers

Yes

Interventions

DRUG

Dasatinib 100 MG

single dose of 100 mg Dasatinib tablets

Locations (1)

CAIMED

Chía, Cundinamarca, Colombia